Skip to main content
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. — Investor Relations & Filings

Ticker · SER ISIN · US00848H1086 LEI · 5493005PJ4B0GQ36ED85 US Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2025-04-07 Regulatory Filings
Country US United States of America
Listing US SER

About Serina Therapeutics, Inc.

https://serinatherapeutics.com/

Serina Therapeutics, Inc. is a biotechnology company that develops novel therapeutics based on its proprietary POZ platform technology. This platform utilizes advanced polyoxazoline (POZ) polymers to create drug delivery systems for small molecule drugs, aiming to improve their therapeutic properties, safety, and efficacy. The technology is designed for programmable and targeted drug delivery to optimize treatments. The company's development pipeline is focused on addressing unmet medical needs in neurological diseases, including Parkinson's disease, as well as pain, cancer, and inflammation. Serina Therapeutics aims to redefine the standard of care by enhancing the performance of new and existing drug candidates.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-04-07 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 7, 2025. It announces that the CEO will present at a conference and references a presentation and a press release as exhibits. The document is short (4134 characters) and primarily serves to disclose an event and furnish related materials, not to provide detailed financial data or a full report. It explicitly states the information is being furnished under Regulation FD and is not filed as part of a registration statement. There are no financial statements or substantive financial analysis included. This fits the profile of a Regulatory Filing (RNS) as a general regulatory announcement and disclosure of an event rather than a full financial report or earnings release.
2025-04-07 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Serina Therapeutics, Inc. It registers additional shares under the company's 2024 Equity Incentive Plan. The document includes legal and procedural information about the registration, incorporation by reference of prior filings (including the Annual Report on Form 10-K), consents, and signatures. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration for employee benefit plans. Form S-8 is specifically used for registering securities to be offered under employee benefit plans. Therefore, this document is best classified as a Regulatory Filing (RNS).
2025-04-02 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus describing the terms of securities to be offered, such as common stock, preferred stock, debt securities, and warrants. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not merely an announcement of a report. Hence, the classification is CAP with high confidence.
2025-04-02 English
FORM 4
Director's Dealing
2025-04-01 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is a Form 424B3 prospectus supplement related to a securities offering, which references and incorporates by attachment the company's Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2024. The text includes the full Form 10-K annual report with detailed sections such as Business, Risk Factors, Management's Discussion and Analysis, Financial Statements, and other typical 10-K content. The presence of the full annual report with comprehensive financial and operational information confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document is classified as an Annual Report (10-K).
2025-03-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.